AbbVie's etentamig meets Phase 3 endpoints in multiple myeloma trial
Tweet Send to a Friend
AbbVie (NYSE: ABBV) reported that its investigational drug etentamig met dual primary endpoints in the Phase 3 CERVINO trial, showing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
